Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.48 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.48 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072398 | 0.85 | TRPA1 (0.55) | TRPA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL30023406 | 0.84 | KLKB1 (0.68) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL10818516 | 0.84 | IKBKB (0.45) | TRPA1ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL418713 | 0.82 | KLKB1 (0.71) | TRPA1KLKB1CTSBMMP9DNMT1 | |
| SCHEMBL925372 | 0.82 | TRPA1 (0.57) | TRPA1KLKB1CTSBMMP9DNMT1 | |
| SCHEMBL27858512 | 0.82 | KLKB1 (0.50) | KLKB1CTSBMMP9DNMT1DNMT3B | |
| SCHEMBL27938470 | 0.82 | KAT8 (0.65) | KAT8ALDH1A1HPGDHSD17B10BACE1 | |
| SCHEMBL4911722 | 0.81 | KAT8 (0.72) | KAT8ALDH1A1KDM4EHSD17B10LCK | |
| SCHEMBL27887200 | 0.81 | KAT8 (0.63) | KAT8ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4097033 | 0.81 | ALDH1A1 (0.54) | TRPA1ALDH1A1MAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000726-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | VANDERBILT UNIVERSITY | 2024-01-04 | — | — | US | disclosed |
| US-11696903-B2 | Compounds and methods for scavenging dicarbonyl electrophiles | VANDERBILT UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11400103-B2 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2022-08-02 | — | — | US | disclosed |
| US-20200383938-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | VANDERBILT UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| US-20200246358-A1 | METHODS OF PREVENTING PLATELET ACTIVATION | VANDERBILT UNIVERSITY | 2020-08-06 | — | — | US | disclosed |
| US-10688109-B1 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10166248-B1 | Methods of preventing platelet activation | VANDERBILT UNIVERSITY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20150265584-A1 | LEVUGLANDIN ADDUCTS HISTONE H4 IN A CYCLOOXYGENASE-2-DEPENDENT MANNER, ALTERING ITS INTERACTION WITH DNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-09-24 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | TRPA1 1954/4885KLKB1 598/4885CTSB 49/4885 |
| US-20240000726-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | OGG1, LGMN, GLO1 | TRPA1 1725/4885KLKB1 836/4885CTSB 210/4885 |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | TRPA1 2883/4885KLKB1 425/4885CTSB 34/4885 |
| US-20200383938-A1 | COMPOUNDS AND METHODS FOR SCAVENGING DICARBONYL ELECTROPHILES | OGG1, LGMN, GLO1 | TRPA1 1725/4885KLKB1 836/4885CTSB 210/4885 |
| US-10166248-B1 | Methods of preventing platelet activation | PFKP, PLG, PRKG1 | TRPA1 3147/4885KLKB1 25/4885CTSB 1049/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885KLKB1 1267/4885CTSB 37/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | TRPA1 3839/4885KLKB1 1267/4885CTSB 37/4885 |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | TRPA1 449/4885KLKB1 1654/4885CTSB 1591/4885 |
| US-10688109-B1 | Methods of preventing platelet activation | PFKP, PLG, PRKG1 | TRPA1 3147/4885KLKB1 25/4885CTSB 1049/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885KLKB1 1267/4885CTSB 37/4885 |
| US-20200246358-A1 | METHODS OF PREVENTING PLATELET ACTIVATION | PLG, PLA2G7, PLAT | TRPA1 2568/4885KLKB1 899/4885CTSB 706/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | TRPA1 3960/4885KLKB1 1312/4885CTSB 59/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | TRPA1 1512/4885KLKB1 883/4885CTSB 53/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885KLKB1 1267/4885CTSB 37/4885 |
| US-11400103-B2 | Methods of preventing platelet activation | PLG, PLA2G7, PLAT | TRPA1 2568/4885KLKB1 899/4885CTSB 706/4885 |
| US-20150265584-A1 | LEVUGLANDIN ADDUCTS HISTONE H4 IN A CYCLOOXYGENASE-2-DEPENDENT MANNER, ALTERING ITS INTERACTION WITH DNA | H1-2, H1-4, H1-3 | TRPA1 1983/4885KLKB1 990/4885CTSB 2909/4885 |
| US-11696903-B2 | Compounds and methods for scavenging dicarbonyl electrophiles | OGG1, LGMN, GLO1 | TRPA1 1725/4885KLKB1 836/4885CTSB 210/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | TRPA1 4021/4885KLKB1 1195/4885CTSB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.